Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.

90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.

2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.

400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.

30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.